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The diagnosis and management of CRLM is complex and requires a multidisciplinary team approach for optimal outcomes.
Over the past several decades, the 5-year survival following resection of CRLM has increased and the criteria for resection have
broadened substantially. Even patients with multiple, bilateralCRLM, previously thought unresectable, may nowbe candidates for
resection. Two-stage hepatectomy, repeat curative-intent hepatectomy, and even selected resection of extrahepatic metastases have
further increased the number of patients who may be treated with curative intent. Multiple liver-directed therapies exist to treat
unresectable, incurable patients with adequate survival beneﬁt and morbidity rates.
1.Introduction
In spite of the many advancements in molecular char-
acterization, screening, diagnosis, surgical technique, and
chemotherapeutics over the past several decades, colorectal
cancer (CRC)remains a major health problem in the USA. It
is the third most common cancer in males and females and
is the second leading cause of cancer death [1]. In 2010, 142
570 new cases of CRC in the USA were estimated, and over a
third of these patients will die of their disease [1], usually as
a result of distant metastatic disease.
About 65% of all patients with CRC develop distant
metastasis, the liver being the most common site (40%) [2].
Colorectal liver metastasis (CRLM) may be diagnosed either
synchronous or metachronous with the diagnosis of the
primary tumor. In a recent French epidemiologic study, the
proportion of patients who presented with synchronous and
metachronous liver metastasis was equal: 14.5% of patients
had synchronous CRLM while the rate of metachronous
CRLM at 5 years was also 14.5% [3]. Of all patients with
CRLM, approximately 25% will have metastasis conﬁned to
the liver and be resectable with curative intent [2, 4–6].
Due to therapeutic advances in the management of CRC,
the case-fatality rate associated with CRC decreased by 10%
(33% relative change) between 1990 and 2006 [1]. Data on
the survival of CRC patients with liver metastasis, however,
are not as deﬁned, with 5-year survival ranging in the liter-
ature depending on a number of factors including patient
selection: ﬁve-year survival rates for patients with syn-
chronous and metachronous CRLM in a recent nonselected
population series were 3.3% and 6.1%, respectively, [3]. In
large (>200 patients) series of selected patients published
in the 1990s comprised of patients who underwent curative
resection of CRLM, overall 5-year survival was reported
to range from 32 to 37% [7–9], and more recently, with
the introduction of more eﬀective cytotoxic chemotherapy
agents in the 2000s, 5-year survival following resection of
CRLM has been reported to range from 37 to 58%; [10–14]
available 10-year survival rates in the literature range rather
consistently between 22% and 28% (Table 1).
2.Prognostic FactorsinCRLM
Many prognostic factors have been reported to be associated
with risk of disease recurrence and survival following
hepatic resection of CRLM. In 1997, Yasui et al. developed
a macroscopic classiﬁcation of liver metastasis, classifying
liver metastasis into simple nodular (SN) lesions, which
have a smooth and distinctive border, versus conﬂuent
nodular (CN) lesions, which are multinodular tumors with2 International Journal of Surgical Oncology
Table 1: Selected Large (>200 patients) studies of resection for
CRLM with 5- and 10-year survival.
Survival
First author [ref] Year N 5-Year 10-Year
Gayowski [7] 1994 204 32% NR
Scheele [8] 1995 350 39% 24%
Fong [9] 1999 1001 37% 22%
Choti [10] 2002 226 40% 26%
Abdalla [11] 2004 348∗ 58% NR
Pawlik [12] 2005 557 58% NR
Wei [13] 2006 423 47% 28%
Tomlinson [14] 2007 612 37% 24%
Fortner [15] 2009 293 35% 24%
NR: not reported.
∗Includes 190 patients undergoing resection only, 101 resection and abla-
tion, and 57 ablation only.
irregular borders [18]. Biological behavior and the degree of
invasiveness were diﬀerent between the two groups; vascular
inﬁltration, lymph node metastasis, and invasion of adjacent
viscera were all more common in the CN group versus the
SN group. Five-year survival was 42% in the SN group but
only 23% in the CN group [18].
Other factors subsequently associated with prognosis in
patients with CRLM have included stage of the primary
tumor, interval from primary to metastatic tumor diagnosis,
number and size of metastases, status of surgical margins,
presence of extrahepatic recurrence or metastasis, presence
of satellite lesions, and serum levels of CEA, alkaline
phosphatase,andalbumin[9,16,17,19].Severalgroupshave
used some of these factors to create scoring systems based on
large series of patients undergoing resection of CRLM, such
as those by Nordlinger et al. [16], Fong et al. [9], Schindle
et al. [17], and several others (Table 2).
Some groups, such as Schindle et al., have applied
the scoring system to patients before, as opposed to after,
resection. Colon cancer stage, number of liver metastases,
and serum levels of CEA, alkaline phosphatase, and albumin
wereidentiﬁedasindependentprognosticfactors[17].Based
on these factors, Schindl et al. developed a scoring system
thatstratiﬁed patientsinto3groupswithgood,intermediate,
and poor prognosis: although liver resection improved
survival in all three groups, the 5-year survival of patients
in the poor, moderate, and good prognosis groups were 0%,
20%, and 62% [17]( T a b l e2(c)).
In addition, several groups have developed nomograms
arguing that they prognosticate better than scoring systems
[20–22].Nathan etal.haverecentlycomparedtheprognostic
abilityofseveralcommonscoring systems andsuggested that
conditional survival (CS) estimates (deﬁned as the survival
probability after a given length of survival) may provide
improved prognostication, given that survival probabilities
change over time [23]. For instance, review of an interna-
tional database of 949 patients undergoing curative-intent
resection of CRLM revealed a 5-year overall survival of 45%
and a 10-year survival of 22%, but the 5-year CS (CS5)a t
5 years (i.e., the probability of surviving another 5 years
conditional on already having survived 5 years) was 50%
[23].
3.Managementof Patientswith
Resectable CRLM
3.1. Surgical Considerations Regarding Chemotherapy. The
use and timing of chemotherapy in patients with CRLM
remains a subject of much debate and was recently the
subjectofaneducationalreviewseriesoncontroversiesinthe
management ofCRLM[24,25].Chemotherapymaybegiven
prior(neoadjuvant) tothecolectomy,betweenthecolectomy
and the hepatectomy, or after both the hepatectomy and the
colectomy, which themselves may be staged or simultaneous.
Few would disagree that a patient with a low-risk solitary
metachronous CRLM should proceed directly to resection
or that in cases of multiple, bilateral, synchronous CRLM,
neoadjuvant chemotherapy is preferred. However, while
some surgeons [25] argue that treatment of not only
synchronous, but also most patients with CRLM should
start with chemotherapy (Figure 1), others [24]h a v ea r g u e d
that the traditional paradigm ofrecommending neoadjuvant
chemotherapy for resectable synchronous CRLM should be
reconsidered, citing increased postoperative complications
related to chemotherapy-induced hepatotoxicity, the rarity
of a complete pathologic response to chemotherapy, and an
inability to identify during a short course of neoadjuvant
therapy those patients who may not beneﬁt from resection,
such as those with aggressive, occult, extrahepatic disease.
Several theoretical advantages of preoperative (both
neoadjuvant for initiallyresectable andconversion chemother-
apy for initially unresectable (Figure 1)) exist in cases of
synchronous CRLM. These advantages include (1) selection:
it may detect patients with occult, extrahepatic, chemoresis-
tant metastases who could be spared an unhelpful operation,
(2) assessment: it can test the responsiveness of the lesion
to chemotherapy and guide postoperative chemotherapeutic
drug choices, (3) systemic therapy: it can theoretically kill
dormant or micrometastatic cells to increase the chance at
total-body eradication, (4) downstaging: it may decrease the
size of metastases and render more patients resectable [6]o r
the resectable tumors more easily resectable, sparing more
normal parenchyma [26, 27], and (5) prognosis: response
to chemotherapy may predict survival. Support for this last
theoretical advantage has largely come from comparisons
of patients with synchronous CRLM who either do or do
not receive neoadjuvant chemotherapy [28], from series
of metachronous-only cases [29], or from comparisons of
mixed patients with synchronous and metachronous CRLM
[30], which have suggested that response to neoadjuvant
chemotherapy correlates with better overall survival. How-
ever, more recent data derived from comparisons of patients
whoallreceivedneoadjuvantchemotherapy,andallofwhom
had synchronous disease showed no correlation between
overall survival and response to neoadjuvant chemotherapy
[31].
Surgery is the mainstay of management and the only
chance for a cure for these patients, but recent level IInternational Journal of Surgical Oncology 3
Table 2: Scoring systems.
(a) Nordlinger prognostic system
Risk N No. of risk factors 2-year survival
Low 305 0–2 79%
Intermed 738 3-4 60%
High 230 5–7 43%
R i s kf a c t o r sa r e( 1 )a g e> 60 years, (2) extension of primary CRC into serosa, (3) node-positive primary CRC, (4) time interval from primary CRC to
CRLM < 2 years, (5) size of largest CRLM ≥ 5cm,(6)numberofCRLM≥ 4, (7) margin less than 1cm [16].
(b) Fong prognostic system
Clinical risk score for tumor recurrence
Survival
%
Risk factors 1yr 2yr 3yr 4yr 5yr Median (months)
0 9 37 97 26 06 0 7 4
1 9 17 66 65 44 4 5 1
2 8 97 36 05 14 0 4 7
3 8 66 74 22 52 0 3 3
4 7 04 53 82 92 5 2 0
5 7 14 52 71 41 4 2 2
Risk factors are (1) node-positive primary CRC, (2) time interval from primary CRC to CRLM < 1y e a r ,( 3 )n u m b e ro fC R L M> 1, (4) size of largest
CRLM > 5cm,(5)CEA> 200ng/mL (reproduced from [9]).
(c) Schindl prognostic system
Risk N Prognostic score Median survival (months) 5-year survival (%)
Good 33 0–10 36 62
Mod 172 11–25 34 20
Poor 65 >25 11 0
Prognostic score = [(4 × Dukecode) + (6 × Metcode3) + (6 × lnAlkphos)+ (2 × lnCEA) − Albumin] + 22, where Dukecode indicates Dukes stage A/B
(score, 0) or C (score, 1), Metcode3, 1 to 3 metastases (score, 0) or more than 3 metastases (score, 1), lnAlkphos, natural logarithmic function of the
serum concentration of alkaline phosphatase (U/L), lnCEA, natural logarithmic function of the serum concentration of CEA (µg/L), and Albumin, the
serum concentration of albumin (g/dL) [17].
data (the EORTC Intergroup trial 40983) have suggested a
survival beneﬁt associated with perioperative chemotherapy
using FOLate, 5-Fluorouracil, and OXaliplatin (FOLFOX)
[32].The EORTCtrial studied364patientsfrom78 hospitals
and compared the progression-free survival in patients who
received perioperative chemotherapy with that of patients
who underwent resection alone. Six cycles of FOLFOX were
administered before and after resection in patients with up
to four liver lesions and histologically proven CRC. There
wasastatisticallysigniﬁcantabsoluteincreaseinprogression-
free survival of 7.3% in randomized patients at 3 years but
not in the intention-to-treat analysis [32]. Although peri-
operative chemotherapy is associated with longer survival
than resection alone, and despite the numerous theoretical
advantages associated with its use, there are signiﬁcant
disadvantages. These include delaying surgery, progression
of chemotherapy-unresponsive CRLM from resectable to
unresectable during neoadjuvant therapy, a higher rate of
reversible surgical complications, chemotherapy-associated
liver injuries, and, counterintuitively, excessive response of
the metastases making them diﬃcult to ﬁnd at surgical
exploration [24, 25].
Among these disadvantages, chemotherapy-associated
hepatotoxicity likely receives the greatest attention from
surgeons evaluating patients with CRLM [33]. At least two
types of histologically identiﬁable injuries have been identi-
ﬁed: fatty liver changes such as steatosis and steatohepatitis
(associated with ﬂuorouracil and irinotecan) and vascular
sinusoidal injury (associated with oxaliplatin). Many retro-
spective studieshavefocusedonthecorrelationbetweenout-
come (namely, complications) and chemotherapy-associated
hepatotoxicity, some ﬁnding that hepatotoxicities such as
steatosis [34] and steatohepatitis [35] independently pre-
dicted postoperative morbidity and mortality, respectively,
and some ﬁnding no association between chemotherapy-
associated hepatotoxicity and complications [36]. Results
from the prospective EORTC trial, which randomized 364
patients into a surgery-only group and a perioperative
chemotherapy group, revealing a small increase in the
reversible postoperative complications in the chemotherapy
groupbutnodiﬀerenceinmortality,likelybestapproximates
t h et r u ee ﬀect [32].
Regarding the so-called “targeted” or “biologic” ther-
apies, those aimed at vascular endothelial growth factor4 International Journal of Surgical Oncology
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Figure 1: Simpliﬁed ﬂow diagram of the managementof CRLM. “Resectability” is deﬁned in the text. See text for the abbreviations.
(VEGF) and epidermal growth factor receptor (EGFR)
deserve mention. Bevacizumab (Avastin) is a monoclonal
antibody that targets VEGF and has recently been shown
to result in signiﬁcantly improved survival of patients
with metastatic colorectal cancer [37]. Similarly, the EGFR
inhibitorscetuximab andpanitumumabhaverecentlyshown
activity in patients with CRLM whose tumors have nonmu-
tated (wild-type) KRAS (reviewed in [38]). Due to increased
risk of bleeding and impaired wound healing [38, 39],
b e v a c i z u m a bi st y p i c a l l yw i t h h e l df o r6 – 8w e e k sp r i o rt o
operation by most surgeons. The use of these targeted
agentshasnotbeenassociatedwithsigniﬁcant hepatotoxicity
[40–42]. The eﬀect of bevacizumab on liver regeneration,
however, is less clear, given that some studies have found
no signiﬁcant impairment in regeneration after portal vein
occlusion [40] while other data suggest that patients who are
older than 60 year or who receive more than ≥6c y c l e so f
bevacizumab had attenuated hypertrophy [43]. Some data
have even suggested a protective eﬀect on liver parenchyma
exposed to cytotoxic chemotherapy, especially oxaliplatin-
based regimens [44, 45], which is consistent with the
observation that VEGF is implicated in vascular sinusoidal
injury [46].
3.2. Staged versus Simultaneous Resection of the Primary
CRC and the CRLM. In addition to the decision regarding
the timing of chemotherapy relative to the hepatectomy,
the planning of the colectomy relative to the hepatectomy
requires careful consideration in cases of synchronous
and resectable CRLM. These patients may undergo eitherInternational Journal of Surgical Oncology 5
Table 3: Staged versus simultaneous resection: 5-year survival and morbidity.
First author [ref] Year Design Simultaneous Staged
N Age 5YS Morbidity N Age 5YS Morbidity
Vogt [47] 1991 Retro 19 NR 39% 5.3% 17 NR 0% 18%
Jaeck [48] 1999 Retro 28 56 NR 18% 31 60 NR 16%
Martin [49] 2003 Retro 134 64 NR 49% 106 61 NR 67%
Weber [50] 2003 Retro 35 58 21% 23% 62 60 22% 32%
Tanaka [51] 2004 Retro 39 64 53% 28% 37 65 47% 16%
Chua [52] 2004 Retro 64 63 29% 53% 32 61 43% 41%
Thelen [53] 2007 Retro 40 60 53% 18% 179 60 39% 25%
Turrini [54] 2007 Retro 57 60 32% 21% 62 59 25% 31%
Yan [55] 2007 Retro 73 60 36% 32% 30 59 37% 43%
Capussotti [56] 2007 Retro 70 65 31% NR 57 60 32% NR
Vassiliou[57] 2007 Retro 25 63 28% 72% 78 61 31% 76%
Reddy [58] 2007 Retro 135 57 NR 44% 475 58 NR 27%
Slupski [59] 2009 Retro 28 59 45% 14% 61 60 38% 13%
Martin [60] 2009 Retro 70 58 NR 56% 160 61 NR 55%
Retro: retrospective; 5YS: 5-year survival. “Simultaneous”and “Staged” refer to resection of the primary CRC tumor and the CRLM.
a combined resection of the colon and liver disease or a
staged resection of the primary CRC and the metastatic liver
disease at two separate operations. Typically, the primary
CRC is resected ﬁrst, since it may cause current or imminent
symptoms such as obstruction or bleeding. However, in
select cases where the liver disease is marginally resectable
and the primary CRC is small, the liver resection may
be performed ﬁrst to avoid progression of the CRLM to
unresectability.
Procedure choice and order must be tailored to the
individual patient, and few data exist to guide this decision.
Surgeons should consider the complexity of both the hepa-
tectomy and the colectomy, the ability to achieve adequate
exposure with a single incision, the level of individual
technical abilities, and the likelihood of progression of
colonic symptoms or progression of the CRLM. Most of the
literature available (Table 3) is retrospective and addresses
predominantlytheriskofmorbidityandmortalityassociated
with the two approaches. Two recent systematic reviews have
summarized this literature. Hillingso and Wille-jorgensen
included 16 articles and found that all contained signiﬁcant
bias,sincethecharacteristicsofthestagedandthesimultane-
ous groups were not usually equivalent:staged patients more
often had left-sided colon primary tumors and larger, more
numerous, and bilateral liver metastases, whereas patients
withright-sidedcolonprimariesandpatientswithsmall liver
lesions in which a curative resection could be achieved with
a minor resection were more likely to have the combined
[61]. They recommended, on the basis of only level-II to
-III evidence (grade C recommendation) that combined
resections be performed in appropriately selected patients
since this approach is associated with a shorter length of
stay and less morbidity, with similar ﬁve-year survival [61].
A second systematic review by Chen et al., suﬀering from
many of the same biases, evaluated 14 studies comprising
2,204 patients comparing simultaneous and staged resec-
tions and found that patients undergoing simultaneous
resections had a similar mean operative time and blood
loss and shorter length of stay and lower morbidity rate
[62].
In general, small, especially left-sided, CRLM are easily
accessible via the standard midline incisions used for the
colectomy and may be safely combined with most colorectal
resections [58]. Even complex resections such as lower
anterior resections and abdominoperineal resections may
be performed simultaneously with minor hepatectomies.
Similarly, a straightforward right hemicolectomy may be
combined with a larger hepatectomy. In some cases of
multiple, bilateral, synchronous CRLM, a colon resection
m a yb ec o m b i n e dw i t ho n es t a g eo fat w o - s t a g el i v e r
resection, as discussed below.
3.3. Multiple Bilateral Liver Metastases. The extent of disease
amenable to curative-intent surgery (CIS) has increased in
recent years. The now-historic teaching that the determinant
of resectability in CRLM was a certain size or number
of metastases fell by the wayside once it became clear
that what matters most is not what is resected, but rather
what is left behind, namely, negative margins and adequate
functional liver parenchyma (>20% of a healthy liver) with
preserved inﬂow, outﬂow, and bile drainage. Three main
paradigm shifts in the treatment of bilateral CRLM have
occurred to achieve resection of more extensive CRLM:
(1) a trend toward parenchyma-sparing approaches over
time, (2) increasing use of ablation and repeat CIS, and
(3) the use of a 2-stage hepatectomy.
Although not exclusive to cases of multiple, bilateral
CRLM, the trend toward parenchyma-sparing approaches
was exempliﬁed at Memorial Sloan-Kettering Cancer Center
(MSKCC) in a report of their experience in 440 patients
undergoing 443 procedures over an 11-year period from
1992 to 2003 [63]. Of these patients, only 8.4% had
synchronous lesions. An acceptable 29% rate of major com-
plications and a 5.4% 90-day mortality rate were observed.6 International Journal of Surgical Oncology
Over time, the operative technique tended toward a decrease
in major resections and an increase in smaller multiple
resection and ablations, which correlated with a decrease
in blood loss, hospital stay, and 90-day mortality, but no
diﬀerence in disease-speciﬁc survival and liver recurrence
[63].
Between 20% and 30% of patients with CRLM (without
extrahepatic disease) have such extensive bilateral liver dis-
ease; however,that completeextirpation at asingle operation
is not possible while maintaining an adequate future liver
remnant (FLR) [64, 65]. These patients may be candidates
for a 2-staged hepatectomy, in which a portion of the
liver disease is removed and the contralateral portal vein is
occluded, followed by a period of typically 1 to 3 months
to allow hypertrophy of the remaining liver and a curative-
intent, second-stage hepatectomy (Figures 1 and 2). Portal
veinocclusionistypically performed eitherby intraoperative
ligation (PVL) or subsequent percutaneous embolization
andwhenadequate,inducessigniﬁcanthypertrophy,increas-
ing the size of the FLR to decrease the risk of postoperative
liver insuﬃciency.
Whether to undertake the minor or the major liver
resection ﬁrst remains debatable. Performing the major
resection ﬁrst was the approach taken in the seminal report
by Adam et al., in which 16 patients underwent systemic
chemotherapy followed by resection of the largest possible
number of metastases in a ﬁrst stage, followed by a second
hepatectomy 4 months later. The mortality was 0%, and
the morbidities for the ﬁrst and second stages were 31%
and 45%, with a 3-year survival of 35%. Although other
groups have also opted for the major-ﬁrst approach [66],
most centers performing 2-stage hepatectomy perform the
minor hepatectomy ﬁrst [65]. The minor-ﬁrst approach
oﬀers several advantages, including avoiding intraoperative
manipulation of the FLR during the higher-risk second
stage, improving selection of patients eligible for major
hepatectomies since those with progressive disease may
be spared a major procedure, and removing metastatic
disease from the hemiliver to undergo hypertrophy, since
theoretically (and observationally [67]) tumors in liver
undergoing hypertrophy may grow faster than those in
liver deprived of portal blood ﬂow (although concomitant
intraarterial chemotherapy may mitigate such growth [68]).
When carefully applied to selected patients, 3-year survival
ranging from 35% to 86% is achievable, comparable in some
studies to survival following a planned one-stage resection
[65, 69].
3.4. Recurrence after Curative-Intent Surgery. Patterns of
recurrence following CIShavebeen studiedin a recent,large,
international, multi-institutional analysis of 1669 patients
undergoing resection only (90%), resection plus ablation
(8%), or ablation alone (2%) [70]. Within 2 years, most
patients developed a recurrence, either intrahepatic only
(43%), extrahepatic only (36%), or intra- and extrahepatic
(21%) [70]. Patients selected to undergo resection combined
with ablation as their initial operation had a median of
6 metastases; recurrence, but not survival, was signiﬁcantly
associated with the number of lesions ablated [71]. Among
all patients who developed an intrahepatic recurrence,
irrespective ofwhether theinitial CISwas resection, ablation,
or both, nearly 40% were candidates for repeat CIS, and a
small subset underwent a third and fourth CIS with similarly
low morbidity and mortality [72], a trend that begins to
render CRLM akin to a chronic disease. With subsequent
CIS [72], the extent of hepatic resection not surprisingly
decreased signiﬁcantly and RFA was more frequently used
(>20%, cf. <10% in the ﬁrst CIS [70]). The ﬁve-year survival
following the ﬁrst, second, and third CIS was 47.1%, 32.6%,
and 23.8%, respectively, [72].
4.Managementof Patientswith
anInitially UnresectableCRLM
4.1. Chemotherapy versus Resection of the Primary CRC in
Patients with Unresectable CRLM. For the approximately
75% of patients with CRLM who are unresectable even by 2-
stage hepatectomy, several treatment strategies exist. Criteria
for unresectability of CRLM are typically considered to be
major liver vascular involvement (e.g., of all 3 hepatic veins,
the portal vein bifurcation, or the retrohepatic vena cava),
bilateral dissemination requiring liver resection that would
leave an inadequate FLR, and multiorgan or unresectable
uniorgan extrahepatic disease [8, 24, 68, 73–75].
The best treatment strategy for unresectable CRLM with
synchronous asymptomatic colorectal cancer is debatable
[76, 77]. Two treatment options debated are CRC resection
followed by chemotherapy or chemotherapy followed by
colon resection only if the patient develops complications
of the CRC or the CRLM is downstaged to resectability
(see below). Throughout the 1990s, approximately 66%
[78] to 72% [79] of patients with unresectable synchronous
CRLM underwent resection of the primary CRC, although
this predominant approach has been recently challenged,
given recent improvements in systemic chemotherapy
[74, 79, 80].
Advocates of resecting the bowel cancer ﬁrst cite advan-
tages of precise deﬁnition of nodal and peritoneal status,
prevention of local complications of progression, a theo-
retical advantage of a reduction of total-body neoplastic
mass, psychological beneﬁt for the patient, and data showing
as u r v i v a la d v a n t a g e[ 75, 76, 78, 81]. Proponents of the
chemotherapy-alone or chemotherapy-ﬁrst approach cite
advantages ofavoidanceofpostoperative mortality and mor-
bidity, immediate treatment of the primary and metastatic
disease with the potential to downstage unresectable CRLM
to resectability, a low frequency of complications from
unresected tumors, and data showing equivalent survival
beneﬁts [24, 74, 80].
In an eﬀort to better stratify patients with unresectable
CRLM according to risk of postoperative death, Vibert et al.
performed a multivariate analysis that identiﬁed age >75
y e a r sa n dl i v e rc y t o l y s i s( A S T> IU/L) as criteria that served
as independent predictors of early postoperative death in
patients who, they argued, should therefore not undergo
CRC resection: the 30-day postoperative mortality rate was
15% with neither criterion, 44% with one criterion, and
100% when both criteria were met [74].International Journal of Surgical Oncology 7
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CRLM two-stage approach
Figure 2: Example of patient with bilateral hepatic metastases managed with a two-stage hepatectomy approach. (a) During the ﬁrst stage,
the disease in the left hemiliver was resected. (b) During the subsequent second stage, a formal right hemihepatectomy was performed to
extirpate the residual disease in the right hemiliver.
In symptomatic patients, the decision for initial therapy
is more straightforward and depends predominantly on the
operative risk of the patient: endoscopic stents for high-
risk patients and palliative resection in low-risk patients.
In fact, among patients who receive initial chemotherapy
with modern combination regimens, the vast majority of
patients never require palliation of their primary tumor.
Poultsides et al. evaluated 233 consecutive such patients
with synchronous CRLM and an unresected primary CRC
who received initial triple-drug regimens (oxaliplatin- or
irinotecan-based) and found that only 7% required emer-
gency operations and only 4% required nonoperative palli-
ation (e.g., stenting) for complications of the primary CRC
[82].
4.2. Downstaging from Unresectable to Resectable CRLM with
Systemic Chemotherapy. As discussed above, a major advan-
tage of initial chemotherapy in patients with unresectable
CRLMistheimmediate treatment ofthelivermetastases and
the possibility to downstage them to resectability (Figure 1).
In a retrospective series of nearly 1500 patients with CRLM,
Adam et al. found that among 1104 unresectable patients
treated with systemic chemotherapy, 138 (12.5%) had a
response suﬃciently robust to allow for curative-intent
resection, with an overall 5-year survival of 33% [6].
Similarly, Nuzzo et al. compared 60 initially resectable
patients with 42 initially unresectable patients receiving
irinotecan-based chemotherapy and found that 15 (35.7%)
of the latter group were converted from unresectable to
resectable CRLM [83]. Operative complications, margin
status, and 3-year overall survival (71% and 73%, resp.) were
similar in both groups, although 3-year disease-free survival
was higher in the primarily resectable patients (58%) than in
the primarily unresectable but downstaged patients (31%);
recurrence rates were 28% and 53%, respectively, and half
of those recurrences in the latter group were reresected with
median survival ranging from 9 to 67 months [83].
Selzner et al. have studied the combination of PVL
and intraarterial chemotherapy to downstage unresectable
CRLM with acceptable morbidity [68]. Of 11 patients
included in this very small study, 6 had a radiographic
response to chemotherapy and 4 were suﬃciently down-
staged to allow curative-intent resection; 2 of these died
at 20 months and 2 were alive at 26 and 40 months.8 International Journal of Surgical Oncology
Unlike other studies not using intraarterial chemotherapy
in combination with portal vein occlusion [67], this small
study found that the growth rate of liver metastases in
the regenerating hemiliver was not accelerated, despite
parenchymal regeneration [68].
4.3. Nonoperative Liver-Directed Therapy. There are three
broad categories of nonoperative liver-directed therapy:
transarterial therapies,ablativetherapies,andradiotherapies.
All three are often reserved for cases in which a complete
resection is not possible, either due to patient or tumor
prohibitive factors. Overlap exists among these approaches
and between them and system chemotherapy, with multiple
approaches available for use in an individual patient.
4.4. Transarterial Therapies. Transarterial therapies include
bland (simple thrombotic) transarterial embolization (TAE)
alone, transarterial chemoembolization (TACE), continuous
infusion via hepatic arterial infusion (HAI) pumps, isolated
hepatic perfusion (IHP), and intraarterial radiotherapy
(IART).Becauselivertumorstypicallyreceivepredominantly
arterial and not portal blood ﬂow [84, 85] and because one
of the greatest disadvantages of systemic chemotherapy is
systemic toxicity, regional transarterial chemotherapy oﬀers
an attractive treatment option for unresectable CRLM. TAE
and TACE have been directly compared in small trials with
similar median survival results (8–12 months) [86, 87].
Given the theoretical advantage of adding a chemotherapeu-
tic agent (namely, the possibility of additive or synergistic
eﬀect of cytotoxicity from chemotherapy and ischemia from
embolization), TACE is more commonly used than TAE. A
larger, more recent series of 245 TACE treatments performed
in 121 patients reported a 27-month overall median survival
(from the development of the CRLM) using chemoem-
bolization with cisplatin, doxorubicin, and mitomycin C
as the chemotherapeutic agents [88]. Because TACE is
predominantly studied in the treatment of hepatocellular
carcinoma, its role in CRLM remains to be better elucidated.
HAI was ﬁrst studied as sole treatment in the treatment
of unresectable CRLM and has been compared to systemic
chemotherapy alone, with most studies showing higher
response rates with HAI, but not necessarily higher survival
rates (ranging from 12–20 months) [89, 90]. Subsequently,
HAI in combination with systemic chemotherapy has been
found to achieve a response rate of 88% and median survival
of 36 months [91]. HAI, however, has several disadvantages,
which are made largely moot by the fact that it is performed
in very few centers and therefore not available to the vast
majority of patients with unresectable CRLM.
IHP was ﬁrst reported in 1961 [92] and has since been
studied using both operative and percutaneous approaches
in a variety of patient populations with liver metastases
[93]. Alexander et al. recently reported on factors associated
with outcome in 120 patients from 1994 to 2004 at the
National Cancer Institute with unresectable CRLM (median
8 metastases) who underwent IHP with either melphalan,
tumor necrosis factor, or both [94]. A radiographic response
rate of 61% and a median overall survival of 17 months
wereobserved,butonlythemelphalangroupshadsigniﬁcant
association with radiographic response. Post-IHP HAI was
performed in 38% of patients and was independently
associated with improved survival [94]. In a European case-
control study of patients with unresectable CRLM (median
number not reported) from the same time period, IHP
with melphalan (N = 99) was compared with systemic
chemotherapy (N = 111)using capecitabine,irinotecan,and
oxaliplatin and no diﬀerence in overall survival was detected
[95]. Because the IHP technique and melphalan doses used
in these studied diﬀered, comparison is diﬃcult, but the
ability to deliver high doses of chemotherapy to the cancer-
burdered organ with limited systemic toxicity is certainly
attractive.
IART is the delivery of radiotherapy, typically Yttrium-
90 (the only currently FDA-approved intraarterial therapy),
a high-energy beta-particle-emitting radioisotope incorpo-
rated onto glass or resin microspheres, into the hepatic arte-
rial system. Sharma et al. in a 2007 phase-I study compared
ytrrium-90 IART with FOLFOX for unresectable CRLM
(N = 20). Radiographic responses were observed in 90%
of patients and stable disease in 10%; median progression-
free survival was 9.3 months [96]. A recent Cochrane study
[97] found a single randomized study comparing IART plus
systemic chemotherapy versus systemic chemotherapy alone
[98],which found a signiﬁcant improvement in progression-
free survival associated with IART, with no diﬀerence in
quality of life.
4.5. Ablative Therapies and Radiotherapies. Ablation and ex-
ternal beam radiation may both be used in the pallia-
tive treatment of unresectable CRLM [99], although these
modalities have a less prominent role than transarterial
therapies.
5.CRLMinthePresenceofExtrahepaticDisease
T h ep r e s e n c eo fe x t r a h e p a t i cd i s e a s e( E H D )i nc a s e so f
CRLM presents a unique challenge to the patient and the
surgeon. Although traditionally considered a contraindica-
tion to surgical treatment, resection of EHD is appropriate
in highly selected patients. In a recent series of 1369
patients undergoing resection of CRLM from 1992 to 2007
at MSKCC, 127 underwent concomitant resection of EHD
located in the lung (27%), portal lymph nodes (21%),
adjacentstructureslocallyinvaded,includingthediaphragm,
portal vein, vena cava, or right adrenal/kidney (16%),
“other” single-site metastases, including ovary, retroperi-
toneal lymph nodes, colorectal recurrence, subcutaneous
tissue, and mediastinal lymph nodes (16%), the peritoneum
(12%), and multiple sites (8%) [100]; 5-year survival
was 26% and 49% in those patients with and without
EHD, respectively. In both the thoracic [101]a n dt h e
g e n e ra ls u r gi c a lo n c o l o gy[ 102] literature,the 5-year survival
after resection of pulmonary and hepatic colorectal liver
metastasis ranges between 30% and 60% in highly selected
patients. Ideal patients to consider for resection are young,
ﬁt, with completely resectable hepatic disease, a single site
of resectable EHD, and demonstrated responsiveness to
systemic chemotherapy.International Journal of Surgical Oncology 9
6.Summary
The diagnosis and management of CRLM is complex and
requires a multidisciplinary team approach for optimal
outcomes. Over the past several decades, the 5-year survival
following resection of CRLM has increased and the criteria
for resection have broadened substantially. Even patients
with multiple, bilateral CRLM, previously thought unre-
sectable, may now be candidates for resection. Two-stage
hepatectomy, repeat curative-intent hepatectomy, and even
selected resection of extrahepatic metastases have further
increased the number of patients who may be treated with
curative intent. Multiple liver-directed therapies exist to
treat unresectable, incurable patients with adequate survival
beneﬁt and morbidity rates.
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